Clostridium difficile infection associated with bismuth-based quadruple therapy (Pylere®) for Helicobacter pylori eradication

被引：3
|
作者：
Castro-Fernandez, Manuel [1 ]
Marques-Ruiz, Alberto [1 ]
Camara-Baena, Sergio [1 ]
Grande-Santamaria, Lourdes [1 ]
机构：
[1] Hosp Univ Valme, Unidad Gest Cin Enfermedades Digest, Seville, Spain
来源：
GASTROENTEROLOGIA Y HEPATOLOGIA | 2019年 / 42卷 / 07期
关键词：
TRIPLE-THERAPY; CLARITHROMYCIN; METRONIDAZOLE;
D O I：
10.1016/j.gastrohep.2019.01.012
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：459 / 460
页数：2
相关论文
共 50 条
  • [21] Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency
    Lee, Moon Won
    Kim, Gwang Ha
    GUT AND LIVER, 2022, 16 (06) : 807 - 808
  • [22] Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication
    Chang, Young Woon
    Shin, Ga Young
    Kim, Jung-Wook
    Moon, Jin-Chang
    Chang, Eun Jee
    Oh, Chi Hyuk
    Jang, Jae-Young
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (04) : 1222 - 1230
  • [23] Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed Helicobacter pylori Infection as 14 Days of Bismuth-Based Quadruple Therapy
    Moon, Sang-Gon
    Lim, Chul-Hyun
    Kang, Hee-Jun
    Choi, Arum
    Kim, Sukil
    Oh, Jung-Hwan
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (15)
  • [24] Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication
    Young Woon Chang
    Ga Young Shin
    Jung-Wook Kim
    Jin-Chang Moon
    Eun Jee Chang
    Chi Hyuk Oh
    Jae-Young Jang
    Digestive Diseases and Sciences, 2022, 67 : 1222 - 1230
  • [25] Bismuth containing quadruple therapy for second line Helicobacter pylori eradication
    Lee, M.
    Lee, B.
    Kim, G.
    Park, E.
    Jeon, H.
    Song, G.
    HELICOBACTER, 2017, 22
  • [26] Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication
    Hwang, Jae Jin
    Lee, Dong Ho
    Lee, Ae-Ra
    Yoon, Hyuk
    Shin, Cheol Min
    Park, Young Soo
    Kim, Nayoung
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (26) : 8132 - 8139
  • [27] Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?
    Phillips, RH
    Whitehead, MW
    Doig, LA
    Sieniawska, CE
    Delves, HT
    Thompson, RPH
    Powell, JJ
    HELICOBACTER, 2001, 6 (02) : 151 - 156
  • [28] FOURTEEN- VERSUS SEVEN-DAY BISMUTH-BASED QUADRUPLE THERAPY FOR SECOND-LINE HELICOBACTER PYLORI ERADICATION
    Hwang, J.
    Lee, D.
    Yoon, H.
    Shin, C.
    Park, Y.
    Kim, N.
    HELICOBACTER, 2015, 20 : 93 - 93
  • [29] Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication
    Jae Jin Hwang
    Dong Ho Lee
    Ae-Ra Lee
    Hyuk Yoon
    Cheol Min Shin
    Young Soo Park
    Nayoung Kim
    World Journal of Gastroenterology, 2015, (26) : 8132 - 8139
  • [30] Generalization and safety of the second-line levofloxacin or Bismuth-based quadruple therapy for Helicobacter eradication
    Hu, Bowen
    Huanfei, Ding
    ASIAN JOURNAL OF SURGERY, 2023, 46 (11) : 5079 - 5079
12345